# Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

> **NCT00343733** · PHASE3 · COMPLETED · sponsor: **Cephalon** · enrollment: 120 (—)

## Conditions studied

- Pain

## Interventions

- **DRUG:** OraVescent Fentanyl

## Key facts

- **NCT ID:** NCT00343733
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 120 (—)
- **Last updated:** 2014-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343733, "Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00343733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*